Benefiting from emerging miniaturized and equipment-free nucleic acid testing (NAT) technologies, fully integrated NAT devices at point of care (POC) with the capability of “sample-in-answer-out” are proceeding at a break-neck speed to eliminate complex operations and reduce the risk of contamination. Like the development of polymerase chain reaction (PCR) technology (the standard technique for NAT), the detection signal of fully integrated NAT devices has evolved from qualitative to quantitative and recently to digital readout, aiming at expanding their extensive applications through gradually improving detection sensitivity and accuracy. This review firstly introduces the existing commercial products, and then illustrates recent fully integrated microfluidic devices for NAT at POC from the aspect of detection signals (i.e., qualitative, quantitative and digital). Importantly, the key issues of existing commercial products and the main challenges between scientific research and product development are discussed. On this basis, we envision that the MARCHED (miniaturized, automatic, reagent-preloaded, commercializable, high-throughput, environment-independent and disposable) NAT devices are expected to be realized in the near future.

受益于新兴的小型化和无设备核酸检测 (NAT) 技术，具有“样本输入-答案输出”能力的完全集成的护理点 (POC) NAT 设备正在以极快的速度进行，以消除复杂的操作并降低污染风险。与聚合酶链反应（PCR）技术（NAT 的标准技术）的发展一样，全集成 NAT 设备的检测信号也从定性发展到定量，最近发展到数字读数，旨在通过逐步提高检测灵敏度来扩大其广泛应用和准确性。本综述首先介绍了现有的商业产品，然后从检测信号方面阐述了最近用于 POC NAT 的全集成微流控设备（即，定性、定量和数字）。重要的是，讨论了现有商业产品的关键问题以及科学研究和产品开发之间的主要挑战。在此基础上，我们设想MARCHED（小型化、自动化、试剂预加载、可商业化、高通量、环境独立和一次性） NAT 设备有望在不久的将来实现。